kiny
Well-known member
- Joined
- Apr 28, 2011
- Messages
- 3,463
http://www.ncbi.nlm.nih.gov/pubmed/23036796
Erythema multiforme major following treatment with infliximab.
Edwards D, Boritz E, Cowen EW, Brown RS.
National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland
BACKGROUND:
The growth in the use of anti-tumor necrosis factor α (TNF-α) agents for treatment of inflammatory conditions has led to increased recognition of the side effects associated with this class of drugs.
CASE DESCRIPTION:
We report a case of a patient who developed erythema multiforme (EM) major with characteristic oral and cutaneous lesions following treatment with the anti-TNF-α medication infliximab therapy for Crohn's disease (CD).
CLINICAL IMPLICATIONS:
To our knowledge, this is the first reported case of infliximab-induced EM secondary to the treatment of CD. It is important for dental clinicians evaluating patients using anti-TNF-α agents to be aware of this possible complication.
Erythema multiforme major following treatment with infliximab.
Edwards D, Boritz E, Cowen EW, Brown RS.
National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland
BACKGROUND:
The growth in the use of anti-tumor necrosis factor α (TNF-α) agents for treatment of inflammatory conditions has led to increased recognition of the side effects associated with this class of drugs.
CASE DESCRIPTION:
We report a case of a patient who developed erythema multiforme (EM) major with characteristic oral and cutaneous lesions following treatment with the anti-TNF-α medication infliximab therapy for Crohn's disease (CD).
CLINICAL IMPLICATIONS:
To our knowledge, this is the first reported case of infliximab-induced EM secondary to the treatment of CD. It is important for dental clinicians evaluating patients using anti-TNF-α agents to be aware of this possible complication.
